Lymphoma (follicular non-Hodgkin's) - rituximab (replaced by TA137)
The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma
| Guidance type: Technology appraisal |
| Date issued: March 2002 |
We will consult on our review plans for this guidance in January 2005. |
| Reference: TA37 |
SummaryThis guidance has been updated and replaced by Lymphoma (follicular non-Hodgkin's) - rituximab. |
| Top |
DocumentsFor healthcare professionals
For patients, carers and the publicBackground information |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below:
|
| Top |
